[Preventing relapse of acute leukemias and myelodysplastic syndromes in post-allograft transplantation: Prophylactic and preemptive strategies (SFGM-TC)].

Autor:	Coiteux V; CHU de Lille, service des maladies du sang, unité de greffe de moelle osseuse et thérapie cellulaire, Lille, France. Electronic address: valerie.coiteux@chu-lille.fr., Abellan I; CHU de Montpellier, service d'onco-hématologie pédiatrique, Montpellier, France., Ahmad I; Hôpital Maisonneuve-Rosemont, université de Montréal, institut universitaire d'hématologie-oncologie et de thérapie cellulaire, Montréal, Québec, Canada., Boisnard A; AP-HP, hôpital Necker-Enfants malades, hématologie adultes, Paris, France., Busquet C; CHU de Limoges, service d'hématologie clinique et thérapie cellulaire, Limoges, France., Ceballos P; CHU de Montpellier, service d'hématologie clinique, Montpellier, France., Coman T; CNRS ERL8254 Imagine Institute, Inserm U1163, Paris, France; Institut Gustave-Roussy, département d'hématologie, Villejuif, France., Godin S; CHU de Lille, service d'hématologie pédiatrique, Lille, France., Hermet É; CHU de Clermont-Ferrand, hématologie clinique, Clermont-Ferrand, France., Marcais A; AP-HP, hôpital Necke-Enfants malades, hématologie adultes, Paris, France; Université Paris Cité, institut Necker, CNRS, Inserm UMR 1151, Paris, France., Mamez AC; Hôpitaux universitaires de Genève, université de Genève, faculté de médecine, département d'hématologie, Genève, Suisse., Quessar A; CHU d'Ibn-Rochd, service d'hématologie clinique et d'oncologie pédiatrique, Casablanca, Maroc., Souchet L; AP-HP, Sorbonne université, Pitié-Salpétrière, service d'hématologie clinique, Paris, France., Magro L; CHU de Lille, service des maladies du sang, unité de greffe de moelle osseuse et thérapie cellulaire, Lille, France., Simon N; CHU de Lille, institut de pharmacie, 59000 Lille, France; Université Lille, ULR 7365, GRITA - groupe de recherche sur les formes injectables et les technologies associées, 59000 Lille, France.
Jazyk:	francouzština
Zdroj:	Bulletin du cancer [Bull Cancer] 2024 Sep 05. Date of Electronic Publication: 2024 Sep 05.
DOI:	10.1016/j.bulcan.2024.06.015
Abstrakt:	Disease relapse remains the first cause of mortality of hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HCT) for acute myeloid and lymphoid leukemia (AML and ALL) and for myelodysplastic syndroms (MDS). More and more patients are eligible for allo-HCT over the years and for many of them, only reduced intensity conditioning is possible, which is associated with a higher risk of relapse. Knowledge and biotechnology allow us to better identify diseases at very high risk of relapse and to measure residual disease before allo-HCT. Planning post-transplant maintenance treatment as part of a prophylaxis strategy is now feasible. Monitoring biomarkers of residual disease and post-transplant chimerism after allo-HCT allows a preemptive strategy. Within the frame of the 14th annual workshops of the Francophone Society for Bone Marrow Transplantation and Cell Therapy, the working group reviewed the literature and discussed novel strategies and therapies used to prevent relapse post-allo-HCT. Innovative drugs have been developed recently. Their toxicity profile allows their use post-allo-HCT, albeit with precaution. We reviewed the use of FLT3 inhibitors for AML, BCR::ABL inhibitors for Philadelphia chromosome for ALL, hypomethylating agents and Bcl-2 inhibitors for AML and MDS. The indications of immunomodulation and infusion of donor lymphocytes have been reviewed. Finally, we outlined methods of follow-up and support for patients receiving these prophylactic treatments. (Copyright © 2024. Published by Elsevier Masson SAS.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu